Skip to main content
. 2017 Jun 14;178(6):906–913. doi: 10.1111/bjh.14792

Figure 2.

Figure 2

(A) Median platelet counts over time and (B) incidence of bleeding events among patients with platelet response in the open‐label extension exposed to romiplostim during the time interval. Q1, Q3 = interquartile range.